Athanor Capital’s Keros Therapeutics KROS Stock Holding History

Athanor Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,547	Closed	-$532K	–	944
2020 Q4	$532K	Buy	+7,547	New	+$476K	0.01%	454

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Athanor Capital's KROS Position: Q1 2021 in Review

Athanor Capital sold out of Keros Therapeutics (KROS) in Q1 2021, closing a stake of 7,547 shares — an estimated $532K sold.

Athanor Capital first reported a position in KROS in Q4 2020 and held it in 1 quarter. The position peaked at $532K in Q4 2020. 83 funds tracked by Wall St. Rank hold KROS as of Q1 2021.

Athanor Capital reported no remaining Keros Therapeutics position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 7,547 Keros Therapeutics shares in Q1 2021, an estimated $532K.
Athanor Capital first reported a position in Keros Therapeutics in Q4 2020 and held it in 1 quarter.
Athanor Capital's Keros Therapeutics position peaked at $532K in Q4 2020.
83 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.